KR20230009390A - Gdc-9545 및 cdk4/6 억제제를 포함하는 병용 요법을 사용한 유방암 치료 - Google Patents

Gdc-9545 및 cdk4/6 억제제를 포함하는 병용 요법을 사용한 유방암 치료 Download PDF

Info

Publication number
KR20230009390A
KR20230009390A KR1020227039518A KR20227039518A KR20230009390A KR 20230009390 A KR20230009390 A KR 20230009390A KR 1020227039518 A KR1020227039518 A KR 1020227039518A KR 20227039518 A KR20227039518 A KR 20227039518A KR 20230009390 A KR20230009390 A KR 20230009390A
Authority
KR
South Korea
Prior art keywords
patient
combination therapy
gdc
palbociclib
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227039518A
Other languages
English (en)
Korean (ko)
Inventor
제니퍼 오'하라 라우흘
산드라 미란
멜라니 캐롤 스미트
마저리 씨. 그린
Original Assignee
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제넨테크, 인크. filed Critical 제넨테크, 인크.
Publication of KR20230009390A publication Critical patent/KR20230009390A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020227039518A 2020-05-12 2021-05-10 Gdc-9545 및 cdk4/6 억제제를 포함하는 병용 요법을 사용한 유방암 치료 Pending KR20230009390A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063023501P 2020-05-12 2020-05-12
US63/023,501 2020-05-12
PCT/US2021/031491 WO2021231250A1 (en) 2020-05-12 2021-05-10 Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor

Publications (1)

Publication Number Publication Date
KR20230009390A true KR20230009390A (ko) 2023-01-17

Family

ID=76250442

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227039518A Pending KR20230009390A (ko) 2020-05-12 2021-05-10 Gdc-9545 및 cdk4/6 억제제를 포함하는 병용 요법을 사용한 유방암 치료

Country Status (11)

Country Link
US (2) US11918561B2 (https=)
EP (1) EP4149476A1 (https=)
JP (3) JP2023500558A (https=)
KR (1) KR20230009390A (https=)
CN (2) CN115551513B (https=)
AU (1) AU2021272100B2 (https=)
CA (1) CA3182018A1 (https=)
IL (1) IL298071A (https=)
MX (1) MX2022014133A (https=)
TW (1) TWI800827B (https=)
WO (1) WO2021231250A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023009374A (es) * 2021-02-16 2023-08-16 Genentech Inc Tratamiento de cancer de mama mediante el uso de tratamientos conjuntos que comprenden gdc-9545 y abemaciclib o ribociclib.
IL315153A (en) * 2022-03-14 2024-10-01 Genentech Inc Combined treatments for breast cancer
CN121337802B (zh) * 2025-10-23 2026-04-14 安徽益普克医药科技发展有限公司 一种雌激素降解剂衍生物及其制备方法与用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102529049B1 (ko) * 2013-08-14 2023-05-08 노파르티스 아게 암의 치료를 위한 조합 요법
KR102358935B1 (ko) * 2014-02-12 2022-02-04 가부시키가이샤 한도오따이 에네루기 켄큐쇼 전자 기기
KR102785474B1 (ko) * 2014-12-18 2025-03-26 에프. 호프만-라 로슈 아게 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도
JP7019422B2 (ja) * 2015-04-29 2022-02-15 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法
KR20180119570A (ko) 2016-03-15 2018-11-02 메리맥 파마슈티컬즈, 인크. 항-ErbB3 항체를 포함하는 병용 요법을 이용한 ER+, HER2-, HRG+ 유방암의 치료
LT3810283T (lt) * 2018-06-21 2023-08-25 F. Hoffmann-La Roche Ag 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti
CA3109090A1 (en) 2018-08-17 2020-02-20 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for the treatment of breast cancer
JP7826068B2 (ja) * 2022-03-11 2026-03-09 本田技研工業株式会社 パワーユニット、及びパワーユニットを搭載した作業機

Also Published As

Publication number Publication date
WO2021231250A1 (en) 2021-11-18
US20240173306A1 (en) 2024-05-30
CN115551513B (zh) 2025-05-02
CN115551513A (zh) 2022-12-30
JP2024102045A (ja) 2024-07-30
TWI800827B (zh) 2023-05-01
AU2024202832A1 (en) 2024-05-23
IL298071A (en) 2023-01-01
JP2023175688A (ja) 2023-12-12
CA3182018A1 (en) 2021-11-18
TW202203913A (zh) 2022-02-01
US11918561B2 (en) 2024-03-05
EP4149476A1 (en) 2023-03-22
AU2021272100A1 (en) 2022-11-17
CN120324434A (zh) 2025-07-18
MX2022014133A (es) 2022-11-30
AU2021272100B2 (en) 2024-09-12
US12303495B2 (en) 2025-05-20
US20210353601A1 (en) 2021-11-18
JP2023500558A (ja) 2023-01-10

Similar Documents

Publication Publication Date Title
US12303495B2 (en) Treatment of breast cancer using combination therapies comprising GDC-9545 and a CDK4/6 inhibitor
JP7667132B2 (ja) Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置
US20260041695A1 (en) Combination therapies for treatment of breast cancer
TWI808648B (zh) 使用包含gdc-9545及gdc-0077之組合療法治療乳癌
AU2024202832B2 (en) Treatment of breast cancer using combination therapies comprising GDC-9545 and a CDK4/6 inhibitor
JP2025530296A (ja) 転移性癌を治療するためのｐｌｋ１阻害剤と抗血管新生剤の併用
HK40084792A (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor
HK40129153A (zh) 使用包含gdc-9545和cdk4/6抑制剂的组合疗法治疗乳腺癌
TWI828060B (zh) 使用包含gdc-9545及阿貝西尼或瑞博西尼之組合療法治療乳癌
HK40084792B (zh) 使用包含gdc-9545和cdk4/6抑制剂的组合疗法治疗乳腺癌
HK40066922A (zh) 使用包含atp竞争性akt抑制剂、cdk4/6抑制剂和氟维司群的组合疗法来治疗乳腺癌

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20221111

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240510

Comment text: Request for Examination of Application